Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Show more

Location: 11 Commerce Drive, Cranford, NJ, 07016, United States | Website: https://citiuspharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

23.82M

52 Wk Range

$0.65 - $12.85

Previous Close

$1.40

Open

$1.37

Volume

640,781

Day Range

$1.25 - $1.37

Enterprise Value

18.42M

Cash

6.089M

Avg Qtr Burn

-5.146M

Insider Ownership

2.90%

Institutional Own.

5.46%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LYMPHIR (Denileukin Diftitox-cxdl, E7777) Details T-cell lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mino-Lok Details Catheter related blood stream infections	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Halo-Lido (CITI-102) Details Hemorrhoids	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pembrolizumab (KEYTRUDA®) + LYMPHIR™ Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.